Medical Advisory Board
Terence J. Colgan, MD
Mount Sinai Hospital
Toronto, Ontario, Canada
Dr. Colgan is an anatomical pathologist, and a practicing cyto- and surgical pathologist, with a particular interest in preventive oncology. Currently, he is Head of the Sections of Gynecological and Cytopathology at the Mount Sinai Hospital and a Professor in the Departments of Laboratory Medicine and Pathobiology and Obstetrics & Gynecology at the University of Toronto. He is actively involved in both teaching and research in pathology, and is a journal editor for Cancer (Cytopathology), Archives of Pathology and Laboratory Medicine, International Journal of Gynecological Pathology, and Journal of Lower Genital Tract Disease. He is a past Chair of the Canadian Society of Cytology and the Society of Canadian Colposcopists, and served on the Executive Board member of the American Society of Cytopathology. For a number of years he was a member of the College of American Pathologist’s Cytopathology Resource Committee. His primary research interests include the application of proteomics to the detection of endometrial disease, new technologies in cervical cancer screening, the screening and diagnosis of genital tract neoplasia, and hereditary cancer. Both the National Cancer Institute of Canada and Canadian Institutes of Health Research have provided support for his research.
Robb W. Glenny, MD
University of Washington
Dr. Glenny is the Division Head of Pulmonary and Critical Care Medicine and Professor of Medicine, Physiology and Biophysics at the University of Washington. Among his ongoing research interests are translational research in acute lung injury and 3D imaging and computer modeling of the respiratory tract. He has published extensively with over 120 papers in prestigious journals during the last 20 years. Dr. Glenny is active in professional society committee work for the American Thoracic Society, American Lung Association, American Heart Association and the American Physiologic Society. He is an associate editor for the Journal of Applied Physiology. He has received several awards for exemplary performance including: National Research Service Award, John Simon Guggenheim Memorial Foundation Award, Giles F. Filley Memorial Award in Respiratory Physiology and Medicine and the Fogarty Senior International Fellowship. He received his BS and MA degrees from Duke University in Biomedical Engineering and Computer Science, his medical doctorate from the University of Virginia, and subsequently specialized in pulmonary physiology. He was a visiting Professor at the Karolinska Institute in Stockholm, Sweden.
Edward P. Ingenito, MD, PhD
Havard Medical School
Dr. Ingenito is an Assistant Professor of Medicine at the Harvard Medical School. He has specialized in critical care medicine and pulmonary medicine at the Brigham and Women’s Hospital in Boston where he also served as Director of the Medical Intensive Care Unit and the Pulmonary Function Lab. Dr. Ingenito has received several awards for outstanding teaching and scholarly work. He has published widely on the subjects of pulmonary function and chronic obstructive pulmonary disease (COPD), and is regarded as a leader in the field. Dr. Ingenito has several patents pending in the area of lung volume reduction therapy for patients who suffer from emphysema. Dr. Ingenito received his BS degree in biology, his MS in Mechanical Engineering and his PhD in Biomedical Engineering from MIT and his Medical Doctorate from the Harvard Medical School.
Gene F. Pawlick, MD
Retired, Kaiser Permanente Medical Group
San Mateo, California
Dr. Pawlick recently retired as the Medical Director of the Kaiser Permanente Medical Group, Regional Reference Laboratories in Berkeley and Richmond, California, where he directed clinical laboratory services from 1993 to 2007. These laboratories comprise the largest reference clinical laboratory organization in the Kaiser Permanente system, performing over 70% of all laboratory testing originating in the Northern California region of 3.3 million health plan members. Dr. Pawlick has been a featured speaker at the American Association of Clinical Chemistry programs and the War College. At Kaiser Permanente, Dr. Pawlick pioneered clinical studies in the area of cancer screening and diagnosis and has participated in related hearings at the FDA as a field expert. He received his BS from the University of San Francisco, his MD from Saint Louis University, and took his residency at Kaiser Hospital in San Francisco. He is a graduate of the Advanced Leadership Program at the Keenan-Flagler School of Business at the University of North Carolina. He is Board Certified in Anatomic and Clinical Pathology. He is also an avid fly fisherman.
James Mulshine, MD, Vice Provost
Dr. Mulshine is the Associate Provost for Research and Vice President Director of Rush Translational Sciences Consortium. His research involves translating basic science into meaningful tools for cancer management, especially for lung cancer management. He has been awarded a number of United States and international patents. His research productivity has been recognized with awards from the Department of Commerce, the Public Health Service, the NIH, and the NCI. He is on numerous editorial and foundation boards involved with lung cancer and prevention research. Dr. Mulshine is also a visiting professor at the University of Tokyo Medical University Clinical Proteome Center. He has worked extensively with academia as well as with industry through collaborative research and development agreements to move cancer management tools into broader clinical application. In addition to his research activities, Dr. Mulshine has had senior administrative responsibilities, such as chairing the NCI’s intramural investigational review board and has been the NCI’s representative to the NIH’s Cooperative Research and development subcommittee.
Javier J. Zulueta, MD, FCCP
University of Navarra School of Medicine
Dr. Zulueta is an Associate Professor in the Department of Medicine at the University of Navarra School of Medicine in Pamplona, Spain, where he is Director of the Pulmonary Service. His research interests include lung cancer screening and the use of molecular biomarkers in early lung cancer detection, acute lung injury and cardio-pulmonary exercise physiology, and he has published over 40 research articles and book chapters. He is a Fellow of the American College of Chest Physicians, Member of the American Thoracic Society and Member of the European Respiratory Society. Dr. Zulueta received his Medical Doctorate from the Universidad Complutense in Madrid, Spain. His specialization in Pulmonary and Critical Care Medicine was at New England Medical Center, Tufts University School of Medicine, Boston, MA.
David C. Wilbur, MD, FACP
Massachusetts General Hospital & Harvard Medical School
Dr. Wilbur is an anatomic pathologist practicing at Massachusetts General Hospital in Boston, Massachusetts, and is Professor of Pathology at Harvard Medical School. He is currently the Director of Clinical Imaging, and was previously the Director of the Cytopathology Unit. He has an active practice in the areas of cytopathology, and gynecologic and breast surgical pathology. He is the co-editor of the 3rd edition of the texbook Comprehensive Cytopathology and his relevant research interests include computerization in pathology, most notably automated screening instrumentation and digital telepathology.
Ralph Aye, MD
Swedish Medical Center
Dr. Ralph Aye is an esophageal and thoracic surgeon at Swedish Medical Center in Seattle, Washington. His current appointments include Clinical Program Leader of Thoracic Oncology at the Swedish Medical Center; the Co-Director, Minimally Invasive Thoracic Surgery Program; Fellowship Director, Advance Minimally Invasive thoracic/Foregut Surgery: and Teaching attending, General Surgery Residency Program, all at the Swedish Medical Center. His clinical interests include: Esophageal Achalasia, Gastro-Esophageal Reflux, Lung Cancer, Mediastinal Masses, Myasthenia Gravis, Thymoma, and Tracheal Problems to name a few. Dr. Aye graduated from the University of Pittsburgh with his residency at New York University and the Swedish Medical Center. He completed a thoracic fellowship in the British health system at Frenchay Hospital in Bristol, England, and a thoracoesophageal fellowship with Dr. Lucius Hill in Seattle, WA.
Harubumi Kato, MD, Ph.D., Vice President
Tokyo University Medical Center
Dr. Kato is Vice President of Tokyo Medical University, and Professor and Chairman of its Department of Surgery. His research interests include surgical oncology, diagnosis and treatment of lung cancer, photodynamic therapy, lung cancer mass survey, molecular biology and proteomics. He has a long list of Japanese and international distinctions including: visiting researcher at the Karolinska Institute, Sweden, President of the Japan Society for Bronchology, President of the International Academy of Cytology, President of the Japan Broncho-esophagological Society, President of the Japanese Association for Chest Surgery, President of the International Association for the Study of Lung Cancer, Chairman of the Japan Society for Laser Surgery and Medicine, Chairman of the Clinical Proteome Center at Tokyo Medical University, Chairman of the Japanese Society of Clinical Cytology and Chairman of the Japan Lung Cancer Society. He sits on various editorial boards for peer-reviewed journals including ACTA Cytologica and Journal of Bronchology. He is the recipient of multiple honors including the Goldblatt Award of the International Academy of Cytology and the Merit Award of the International Association for the Study of Lung Cancer. Dr. Kato received his medical doctorate and PhD from Tokyo Medical University.
Glen J. Weiss, MD, Director of Clinical Research
Cancer Treatment Centers of America
Dr. Glen J. Weiss, MD, serves as the Director of Clinical Research at Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center. Board certified in internal medicine and medical oncology, Dr. Weiss has already completed numerous clinical trials with investigational agents, a few of which have already gone on to receive FDA approval for certain cancers. He also serves as a Clinical Associate Professor and Co-Head of the Lung Cancer Unit of the Cancer and Cell Biology Division at the Translational Genomics Research Institute (TGen) in Phoenix and Clinical Associate Professor at the University of Arizona College of Medicine-Phoenix. Dr. Weiss currently is also the Chief Medical Officer of the CRAB Clinical Trials Consortium, a position he was elected to in 2011. Prior to joining CTCA, Dr. Weiss was affiliated with Piper Cancer Center and the University of Colorado Health Sciences Center. Dr. Weiss earned a medical degree from Sackler School of Medicine in Tel Aviv, Israel. He then completed an internal medicine residency at SUNY-Downstate in Brooklyn, New York. He went on to finish a hematology/medical oncology fellowship at the University of Colorado Health Sciences Center in Aurora, serving as the Chief Fellow in his final year.